USE OF GLUTARYL HISTAMINE TO TREAT RESPIRATORY TRACT INFECTIONS

(19)

(11)

EP 2 767 282 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	03.06.2020 Bulletin 2020/23

(45)	Mention of the grant of the patent:
	15.04.2020 Bulletin 2020/16

(21)	Application number: 12839969.8

(22)	Date of filing: 09.10.2012

(51)

International Patent Classification (IPC):

A61K 9/02^(2006.01)
A61K 31/417^(2006.01)
A61K 31/5383^(2006.01)
A61K 31/7052^(2006.01)
A61K 45/06^(2006.01)

A61K 9/20^(2006.01)
A61K 31/43^(2006.01)
A61K 31/546^(2006.01)
A61K 31/7048^(2006.01)
A61P 11/00^(2006.01)

(86)	International application number:
	PCT/RU2012/000821

(87)	International publication number:
	WO 2013/055258 (18.04.2013 Gazette 2013/16)

(54)	USE OF GLUTARYL HISTAMINE TO TREAT RESPIRATORY TRACT INFECTIONS VERWENDUNG VON GLUTARYLHISTAMIN ZUR BEHANDLUNG VON ATEMWEGSINFEKTIONEN UTILISATION DE LA GLUTARYLHISTAMINE POUR TRAITER LES MALADIES DES VOIES RESPIRATOIRES

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

11.10.2011 RU 2011141288

(43)	Date of publication of application:
	20.08.2014 Bulletin 2014/34

(73)	Proprietors:
	Ltd. "Valenta-Intellekt" Moscow 121471 (RU) Nebolsin, Vladimir Evgenievich Moskovskaya Obl., 143581 (RU)

(72)	Inventors:
	NEBOLSIN, Vladimir Evgenievich Moskovskaya Obl., 143581 (RU) KOLOBUKHINA, Lyudmila Vasilievna Moscow, 127204 (RU)

(74)	Representative: Hoffmann Eitle
	Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München 81925 München (DE)

(56)

References cited: :

WO-A1-2010/134851

DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2011, KOLOBUKHINA L V ET AL: "The efficacy of Ingavirin in the combined treatment of ARVI complicated by tonsilitis", XP002735031, Database accession no. PREV201200299000 & VESTNIK OTORINOLARINGOLOGII, no. 6, 2011, pages 91-95, ISSN: 0042-4668
DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; September 2011 (2011-09), KOLOBUKHINA L V ET AL: "PANDEMIC FLU IN RUSSIA: SPECIAL FEATURES OF A CLINICAL COURSE AND THE ABSENCE OF EARLY ETIOTROPIC THERAPY AS A RISK FACTOR OF SEVERE FORMS OF THE DISEASE", XP002735032, Database accession no. PREV201200054001 & TERAPEVTICHESKII ARKHIV, vol. 83, no. 9, 2011, pages 48-53, ISSN: 0040-3660
DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; May 2010 (2010-05), LENEVA I A ET AL: "Study of the antiviral activity of Russian anti-influenza agents in cell culture and animal models", XP002735033, Database accession no. PREV201000474369 & VOPROSY VIRUSOLOGII, vol. 55, no. 3, May 2010 (2010-05), pages 19-27, ISSN: 0507-4088
DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; July 2004 (2004-07), KOVALEVA V L ET AL: "The effect of a potential drug ingamine on a model of noninfectious pneumonia", XP002735034, Database accession no. PREV200500008302 & KOVALEVA V L ET AL: "The effect of a potential drug ingamine on a model of noninfectious pneumonia", EKSPERIMENTAL'NAYA I KLINICHESKAYA FARMAKOLOGIYA, vol. 67, no. 4, July 2004 (2004-07), pages 30-34, ISSN: 0869-2092
MURRAY N. W.: 'Current and future clinical applications of interferon-gamma in host antimicrobial defense' INTENSIVE CARE MEDICINE vol. 22, no. ISS.4, October 1996, pages S456 - S461, XP055149625
NONIKOV V.E.: 'Pnevmonii: vybor antibakterialnoi terapii.' PULMONOLOGIIA no. 1, 2010, pages 7 - 11, XP055160086 Retrieved from the Internet: <URL:http://www.consilium-medicum.com/artic le/19963> [retrieved on 2013-02-07]

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).